# EDGAR Filing Document

**Accession Number:** 0001640455
**File Stem:** 0000000000-23-003240
**Filing Date:** 2023-3
**Character Count:** 5537
**Document Hash:** 44f04cfacdfef5b64e883c713debd3eb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003240.hdr.sgml**: 20230605

**ACCESSION NUMBER**: 0000000000-23-003240

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230330

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jounce Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001640455
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 454870634
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 780 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-259-3840

**MAIL ADDRESS:**
- **STREET 1:** 780 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001640455-23-000042

## Text-Extract

```

United States securities and exchange commission logo

                            March 30, 2023

       Jacquelyn Fahey Sandell
       Chief Legal Officer
       Jounce Therapeutics, Inc.
       780 Memorial Drive
       Cambridge, Massachusetts 02139

                                                        Re: Jounce
Therapeutics, Inc.
                                                            Schedule 14D-9
filed March 27, 2023
                                                            File No. 005-89831

       Dear Jacquelyn Fahey Sandell:

                                                        We have reviewed your
filing and have the following comment.

               Please respond to this comment by providing the requested
information or advise us as
       soon as possible when you will respond. If you do not believe our
comment applies to your facts
       and circumstances, please tell us why in your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Schedule 14D-9 filed March 27, 2023

       Additional Information and Where to Find It

   1.                                                   The SEC Reference Room
no longer provides a means for shareholders to access periodic
                                                        report filings;
however, those filings are generally available on the SEC's EDGAR system.
                                                        Please revise your
disclosure accordingly.
       General

   2.                                                   This filing incorrectly
uses the EDGAR "tag" for a Schedule 14D-9, when it should be
                                                        filed as a Schedule
14D-9C. All future preliminary communication filings should be
                                                        made under cover of
Schedule 14D-9C. Please confirm your understanding in your
                                                        response letter.
               We remind you that the filing persons are responsible for the
accuracy and adequacy of
       their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
 Jacquelyn Fahey Sandell
Jounce Therapeutics, Inc.
March 30, 2023
Page 2

       Please direct any questions to Christina Chalk at 202-551-3263 or Blake
Grady at 202-
551-8573.

FirstName LastNameJacquelyn Fahey Sandell                 Sincerely,
Comapany NameJounce Therapeutics, Inc.
                                                          Division of
Corporation Finance
March 30, 2023 Page 2                                     Office of Mergers &
Acquisitions
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 30, 2023

Jacquelyn Fahey Sandell  
Chief Legal Officer  
Jounce Therapeutics, Inc.  
780 Memorial Drive  
Cambridge, Massachusetts 02139

**Re: Jounce Therapeutics, Inc.  
Schedule 14D-9 filed March 27, 2023  
File No. 005-89831**

Dear Jacquelyn Fahey Sandell:

We have reviewed your filing and have the following comment.

Please respond to this comment by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Schedule 14D-9 filed March 27, 2023

# Additional Information and Where to Find It

1. The SEC Reference Room no longer provides a means for shareholders to access periodic report filings; however, those filings are generally available on the SEC's EDGAR system. Please revise your disclosure accordingly.

# General

2. This filing incorrectly uses the EDGAR 'tag' for a Schedule 14D-9, when it should be filed as a Schedule 14D-9C. All future preliminary communication filings should be made under cover of Schedule 14D-9C. Please confirm your understanding in your response letter.

We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Jacquelyn Fahey Sandell
Jounce Therapeutics, Inc.
March 30, 2023
Page 2

Please direct any questions to Christina Chalk at 202-551-3263 or Blake Grady at 202-551-8573.

Sincerely,

Division of Corporation Finance
Office of Mergers & Acquisitions